#United States #San Francisco #Securities Class Action #FTC Complaint #Hims & Hers

Hims & Hers Health Under Legal Scrutiny

Hims & Hers Health, Inc. (NYSE: HIMS), a well-known player in the telehealth industry, is currently embroiled in a securities class action lawsuit following allegations of substantial business misconduct. This legal challenge comes in the wake of a serious complaint initiated by the Federal Trade Commission (FTC) that accuses the company of deceptive practices regarding patient data privacy and subscription billing procedures.

Background of the Class Action

Hagens Berman, a law firm known for its work in corporate accountability, is leading the charge on behalf of investors who have suffered losses due to Hims' alleged misconduct. The law firm is urging those who lost money on HIMS stock to step forward before the lead plaintiff deadline set for November 2, 2026. According to the allegations, Hims has made assurances about protecting sensitive health information while simultaneously sharing it with third-party advertisers without proper disclosure.

The claims suggest that between August 4, 2025, and July 29, 2026, Hims misled both consumers and investors regarding its business practices. A significant feature of the lawsuit is the assertion that Hims charged customers for prescriptions almost immediately after they had filled out intake forms, without providing an opportunity for consultation with a medical provider, contrary to their stated policies.

FTC's Allegations

The FTC complaint outlines various charges against Hims, focusing particularly on two critical areas: the improper sharing of consumers' health data with third parties and violations related to subscription billing practices. The allegations reveal that even while promoting a strong commitment to data privacy and user confidentiality, Hims may have leaked sensitive medical information to giants like Meta Platforms (previously Facebook) and Snap through tracking pixels.

Alongside data sharing issues, Hims is accused of practices that violate the Restore Online Shoppers' Confidence Act (ROSCA). This act mandates clear consent for recurring subscriptions. The lawsuit claims that consumers were automatically enrolled in subscription services and faced barriers when trying to cancel, effectively trapping them into continued charges. These practices allegedly led to severe customer dissatisfaction and questioning of the company’s ethical practices.

Market Impact and Reactions

In a swift reaction to the news of the class action and FTC complaint, Hims' stock price plummeted by $4.32, resulting in a 14.7% drop in a single day. This decline erased nearly $970 million from the company’s market capitalization, highlighting the immediate and severe impact of the allegations on investor confidence. Reed Kathrein, a leading partner at Hagens Berman, emphasized that the firm is keen on exploring whether Hims intentionally misled its investors concerning its operational practices, internal controls, and the financial implications of its actions.

Next Steps for Investors and Whistleblowers

For investors who feel they have been adversely affected by these developments, it’s crucial to act swiftly. Hagens Berman is actively seeking participants for the class action, encouraging those with knowledge or information relevant to the case to reach out. Furthermore, the firm is providing information on the SEC Whistleblower program, which incentivizes individuals to report non-public information that could lead to significant financial recoveries for affected parties.

In this case of Hims & Hers Health, the unfolding legal narrative serves as a stark reminder of the vulnerabilities inherent in fast-growing tech-driven health services. As the situation develops, HIMS investors and consumers alike will be watching closely to see how these allegations impact the future of the company and the broader telehealth industry. With significant penalties and regulatory scrutiny looming, Hims’ ability to navigate this storm is uncertain.

For more information or to submit a claim, you can visit Hagens Berman’s investigation page or contact them directly via email or phone.

Conclusion

This class action lawsuit against Hims & Hers Health underscores the complexities and responsibilities that come with handling sensitive health information. It serves to remind both consumers and healthcare service providers of the paramount importance of transparency and ethical standards in the digital age.